je.st
news
POZEN Rating Increased to Buy at Ascendiant Capital Markets
2014-08-09 22:40:07| Biotech - Topix.net
The firm currently has a $10.00 price target on the stock. Ascendiant Capital Markets' price target would suggest a potential upside of 22.25% from the company's current price.
Tags: buy
rating
capital
increased
Category:Biotechnology and Pharmaceuticals
Latest from this category |
All news |
||||||||||||||||||||
|
|
||||||||||||||||||||